Jennison Associates LLC Purchases 3,287 Shares of Becton, Dickinson and Company (NYSE:BDX)

Jennison Associates LLC grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 383,564 shares of the medical instruments supplier’s stock after acquiring an additional 3,287 shares during the quarter. Jennison Associates LLC’s holdings in Becton, Dickinson and Company were worth $93,524,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. OFI Invest Asset Management acquired a new stake in Becton, Dickinson and Company in the 3rd quarter valued at $25,000. Fortitude Family Office LLC bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth about $35,000. Venturi Wealth Management LLC raised its holdings in shares of Becton, Dickinson and Company by 552.0% in the 4th quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 138 shares during the last quarter. Arlington Trust Co LLC bought a new position in Becton, Dickinson and Company in the 4th quarter valued at about $41,000. Finally, Headlands Technologies LLC acquired a new position in Becton, Dickinson and Company during the 3rd quarter valued at about $55,000. Institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Raymond James increased their price objective on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Barclays upped their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $280.00.

Becton, Dickinson and Company Trading Down 0.1 %

NYSE:BDX opened at $233.88 on Tuesday. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32. The firm has a 50-day moving average price of $239.81 and a two-hundred day moving average price of $241.99. The firm has a market cap of $67.57 billion, a price-to-earnings ratio of 55.42, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.73 billion. During the same quarter in the previous year, the firm earned $2.98 earnings per share. The business’s revenue was up 2.6% on a year-over-year basis. On average, equities analysts expect that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.